Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Harris

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
Journal of Drugs in Dermatology : JDD|June 18, 2020
Novel Polymeric Lotion Formulation of Once-Daily Tazarotene (0.045%) for Moderate-to-Severe Acne: Pooled Phase 3 AnalysisEmil A Tanghetti, William Philip Werschler, Edward Lain, et al.
The Journal of Clinical and Aesthetic Dermatology|December 28, 2018
Safety and Efficacy of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination Lotion in the Treatment of Moderate-to-severe Plaque Psoriasis: A Comparison with Halobetasol Propionate 0.05% CreamNeal D Bhatia, David M Pariser, Leon Kircik, et al.
The Journal of Investigative Dermatology|June 3, 2006
Molecular analysis of T-cell receptor beta genes in cutaneous T-cell lymphoma reveals Jbeta1 biasSuzanne M Morgan, Elizabeth Hodges, Tracey J Mitchell, et al.
Journal of Drugs in Dermatology : JDD|March 26, 2019
Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque PsoriasisLeon H. Kircik, Kim A. Papp, Linda Stein Gold, et al.
Journal of Drugs in Dermatology : JDD|June 29, 2019
A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne VulgarisEmil A. Tanghetti, Leon H. Kircik, Lawrence J. Green, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2013
Are needs assessments cost effective in reducing distress among patients with cancer? A randomized controlled trial using the Distress Thermometer and Problem ListWilliam Hollingworth, Chris Metcalfe, Susana Mancero, et al.
The Oncologist|October 5, 2007
HopeRichard T Penson, Fei Gu, Susan Harris, et al.
The American Journal of Cardiology|October 7, 2004
Safety of rosuvastatinJames Shepherd, Donald B Hunninghake, Evan A Stein, et al.
Frontiers in Microbiology|March 7, 2019
Substantial Extracellular Metabolic Differences Found Between Phylogenetically Closely Related Probiotic and Pathogenic Strains of <i>Escherichia coli</i>Justin J J van der Hooft, Robert J Goldstone, Susan Harris, et al.
Clinical Immunology (Orlando, Fla.)|June 21, 2005
Omenn's syndrome occurring in patients without mutations in recombination activating genesAndrew R Gennery, Elizabeth Hodges, Anthony P Williams, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Journal of Drugs in Dermatology : JDD|June 18, 2020
Novel Polymeric Lotion Formulation of Once-Daily Tazarotene (0.045%) for Moderate-to-Severe Acne: Pooled Phase 3 AnalysisEmil A Tanghetti, William Philip Werschler, Edward Lain, et al.
The Journal of Clinical and Aesthetic Dermatology|December 28, 2018
Safety and Efficacy of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination Lotion in the Treatment of Moderate-to-severe Plaque Psoriasis: A Comparison with Halobetasol Propionate 0.05% CreamNeal D Bhatia, David M Pariser, Leon Kircik, et al.
The Journal of Investigative Dermatology|June 3, 2006
Molecular analysis of T-cell receptor beta genes in cutaneous T-cell lymphoma reveals Jbeta1 biasSuzanne M Morgan, Elizabeth Hodges, Tracey J Mitchell, et al.
Journal of Drugs in Dermatology : JDD|March 26, 2019
Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque PsoriasisLeon H. Kircik, Kim A. Papp, Linda Stein Gold, et al.
Journal of Drugs in Dermatology : JDD|June 29, 2019
A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne VulgarisEmil A. Tanghetti, Leon H. Kircik, Lawrence J. Green, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2013
Are needs assessments cost effective in reducing distress among patients with cancer? A randomized controlled trial using the Distress Thermometer and Problem ListWilliam Hollingworth, Chris Metcalfe, Susana Mancero, et al.
The Oncologist|October 5, 2007
HopeRichard T Penson, Fei Gu, Susan Harris, et al.
The American Journal of Cardiology|October 7, 2004
Safety of rosuvastatinJames Shepherd, Donald B Hunninghake, Evan A Stein, et al.
Frontiers in Microbiology|March 7, 2019
Substantial Extracellular Metabolic Differences Found Between Phylogenetically Closely Related Probiotic and Pathogenic Strains of <i>Escherichia coli</i>Justin J J van der Hooft, Robert J Goldstone, Susan Harris, et al.
Clinical Immunology (Orlando, Fla.)|June 21, 2005
Omenn's syndrome occurring in patients without mutations in recombination activating genesAndrew R Gennery, Elizabeth Hodges, Anthony P Williams, et al.
Pageof 6